PCa Commentary #165 – Lutetium-177—PSMA-617 Therapy: Now FDA approved and to be available shortly: The Treatment in Context

by Dr. Ed Weber | May 17, 2022 | PCa Commentary

[Prostate Cancer Commentary Vol. 143 PCa Commentary #143: ANTI-PSMA 177-LUTETIUM RADIOLIGAND THERAPY discusses the mechanism of action of 177Lu therapy, its background and outcome of early studies] (control+click above link to follow or visit...

PCa Commentary #164 – Recurrent Prostate Cancer – An Emerging Management Trifecta:    PSMA PET/CT; Oligometastatic Cancer; Focal CyberKnife Treatment. 

by Dr. Ed Weber | Apr 19, 2022 | PCa Commentary

When the PSA is elevated following initial potentially curative treatment with prostatectomy or radiation therapy, the customary management response has been hormone suppression with Lupron, Degarilix or Relugolix. This Commentary highlights an alternative...

PCa Commentary #163 – DECIPHER GENOMIC CLASSIFIER: Its Risk Predictions Assist in Decision-Making.

by Dr. Ed Weber | Mar 10, 2022 | PCa Commentary, Uncategorized

Heterogeneity is the Achilles heel of prostate cancer staging. Intermediate-risk cancers with Gleason Score 3+4 and 4+3 (i.e., Grade Groups 2 and 3) are especially fraught with this complexity. A report, “Molecular Analysis of Low-Grade Prostate Cancer Using...

PCa Commentary #162 – ACTIVE SURVEILLANCE:  Patient Selection and Monitoring – An Update 

by Dr. Ed Weber | Feb 3, 2022 | PCa Commentary, Uncategorized

[A prior Commentary, Vol. 138, September 2019 https://www.prostatecancerfree.org/pca-commentary-138-active-surveillance-update-and-new-developments/ covered this topic and remains current. This Commentary will build upon it.] Guidelines suggesting ‘best practice’...

PCa Commentary #161 – BIPOLAR ANDROGEN THERAPY (BAT): A TREATMENT OPTION FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).

by Dr. Ed Weber | Jan 21, 2022 | PCa Commentary

The BAT regimen was introduced in January 2015 in a report by Schweizer and his Johns Hopkins colleagues, “Effect of Bipolar Androgen Therapy for asymptomatic men with castration-resistant prostate cancer,” (Sci Transl Med). In their study, 16 men with low to moderate...

PCa Commentary #160 – Gene Mutations in the BRCA Family and PARP Inhibition Therapy

by Dr. Ed Weber | Jan 6, 2022 | PCa Commentary

PARP [poly (ADP-ribose) polymerase] is a nuclear RNA enzyme essential for repair of single strand DNA damage. It is the default program that repairs damaged DNA that remained unrepaired because of deleterious mutations in the BRCA family of genes, a cell’s first...